Myeloid Neoplasms and Clonal Hematopoiesis from the RUNX1 Perspective

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2022 Mar 31

PMID 35354921

Authors

Yoshihiro Hayashi

Yuka Harada

Hironori Harada

Affiliations

Soon will be listed here.

Abstract

RUNX1 is a critical transcription factor for the emergence of definitive hematopoiesis and the precise regulation of adult hematopoiesis. Dysregulation of its regulatory network causes aberrant hematopoiesis. Recurrent genetic alterations in RUNX1, including chromosomal translocations and mutations, have been identified in both inherited and sporadic diseases. Recent genomic studies have revealed a vast mutational landscape surrounding genetic alterations in RUNX1. Accumulating pieces of evidence also indicate the leukemogenic role of wild-type RUNX1 in certain situations. Based on these efforts, part of the molecular mechanisms of disease development as a consequence of dysregulated RUNX1-regulatory networks have become increasingly evident. This review highlights the recent advances in the field of RUNX1 research and discusses the critical roles of RUNX1 in hematopoiesis and the pathobiological function of its alterations in the context of disease, particularly myeloid neoplasms, and clonal hematopoiesis.

Citing Articles

Transcription factor RUNX1 regulates coagulation factor XIII-A (): decreased platelet-megakaryocyte expression and clot contraction in haplodeficiency.

Del Carpio-Cano F, Songdej N, Guan L, Mao G, Goldfinger L, Wurtzel J Res Pract Thromb Haemost. 2025; 9(1):102680.

PMID: 39995753 PMC: 11849627. DOI: 10.1016/j.rpth.2025.102680.

RUNX1 isoforms regulate RUNX1 and target genes differentially in platelets-megakaryocytes: association with clinical cardiovascular events.

Guan L, Voora D, Myers R, Del Carpio-Cano F, Rao A J Thromb Haemost. 2024; 22(12):3581-3598.

PMID: 39181539 PMC: 11608153. DOI: 10.1016/j.jtha.2024.07.032.

Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma.

Palacios-Berraquero M, Rodriguez-Marquez P, Calleja-Cervantes M, Berastegui N, Zabaleta A, Burgos L Blood Adv. 2024; 8(21):5479-5492.

PMID: 39058976 PMC: 11532743. DOI: 10.1182/bloodadvances.2023012522.

Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition.

Zerella J, Homan C, Arts P, Lin X, Spinelli S, Venugopal P Blood. 2024; 144(17):1765-1780.

PMID: 38991192 PMC: 11530364. DOI: 10.1182/blood.2024024607.

Interface-guided phenotyping of coding variants in the transcription factor RUNX1.

Ozturk K, Panwala R, Sheen J, Ford K, Jayne N, Portell A Cell Rep. 2024; 43(7):114436.

PMID: 38968069 PMC: 11345852. DOI: 10.1016/j.celrep.2024.114436.

References

Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M . t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci U S A. 1991; 88(23):10431-4. PMC: 52942. DOI: 10.1073/pnas.88.23.10431. View

Bae S, Yamaguchi-Iwai Y, Ogawa E, Maruyama M, Inuzuka M, Kagoshima H . Isolation of PEBP2 alpha B cDNA representing the mouse homolog of human acute myeloid leukemia gene, AML1. Oncogene. 1993; 8(3):809-14. View

Melnikova I, Crute B, Wang S, Speck N . Sequence specificity of the core-binding factor. J Virol. 1993; 67(4):2408-11. PMC: 240414. DOI: 10.1128/JVI.67.4.2408-2411.1993. View

Link K, Chou F, Mulloy J . Core binding factor at the crossroads: determining the fate of the HSC. J Cell Physiol. 2009; 222(1):50-6. PMC: 2812028. DOI: 10.1002/jcp.21950. View

Sood R, Kamikubo Y, Liu P . Role of RUNX1 in hematological malignancies. Blood. 2017; 129(15):2070-2082. PMC: 5391618. DOI: 10.1182/blood-2016-10-687830. View

Bellissimo D, Speck N . Mutations in Inherited and Sporadic Leukemia. Front Cell Dev Biol. 2018; 5:111. PMC: 5742424. DOI: 10.3389/fcell.2017.00111. View

Ogawa E, Maruyama M, Kagoshima H, Inuzuka M, Lu J, Satake M . PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene. Proc Natl Acad Sci U S A. 1993; 90(14):6859-63. PMC: 47032. DOI: 10.1073/pnas.90.14.6859. View

van Wijnen A, Stein G, Gergen J, Groner Y, Hiebert S, Ito Y . Nomenclature for Runt-related (RUNX) proteins. Oncogene. 2004; 23(24):4209-10. DOI: 10.1038/sj.onc.1207758. View

Ghozi M, Bernstein Y, NEGREANU V, Levanon D, Groner Y . Expression of the human acute myeloid leukemia gene AML1 is regulated by two promoter regions. Proc Natl Acad Sci U S A. 1996; 93(5):1935-40. PMC: 39886. DOI: 10.1073/pnas.93.5.1935. View

10.

Rennert J, Coffman J, Mushegian A, Robertson A . The evolution of Runx genes I. A comparative study of sequences from phylogenetically diverse model organisms. BMC Evol Biol. 2003; 3:4. PMC: 153517. DOI: 10.1186/1471-2148-3-4. View

11.

Levanon D, Glusman G, Bangsow T, Ben-Asher E, Male D, Avidan N . Architecture and anatomy of the genomic locus encoding the human leukemia-associated transcription factor RUNX1/AML1. Gene. 2001; 262(1-2):23-33. DOI: 10.1016/s0378-1119(00)00532-1. View

12.

Challen G, Goodell M . Runx1 isoforms show differential expression patterns during hematopoietic development but have similar functional effects in adult hematopoietic stem cells. Exp Hematol. 2010; 38(5):403-16. PMC: 2854264. DOI: 10.1016/j.exphem.2010.02.011. View

13.

Aronson B, Fisher A, Blechman K, Caudy M, Gergen J . Groucho-dependent and -independent repression activities of Runt domain proteins. Mol Cell Biol. 1997; 17(9):5581-7. PMC: 232406. DOI: 10.1128/MCB.17.9.5581. View

14.

Imai Y, Kurokawa M, Tanaka K, Friedman A, Ogawa S, Mitani K . TLE, the human homolog of groucho, interacts with AML1 and acts as a repressor of AML1-induced transactivation. Biochem Biophys Res Commun. 1998; 252(3):582-9. DOI: 10.1006/bbrc.1998.9705. View

15.

Draper J, Sroczynska P, Leong H, Fadlullah M, Miller C, Kouskoff V . Mouse RUNX1C regulates premegakaryocytic/erythroid output and maintains survival of megakaryocyte progenitors. Blood. 2017; 130(3):271-284. PMC: 5833261. DOI: 10.1182/blood-2016-06-723635. View

16.

Liu X, Zhang Q, Zhang D, Zhou C, Xing H, Tian Z . Overexpression of an isoform of AML1 in acute leukemia and its potential role in leukemogenesis. Leukemia. 2009; 23(4):739-45. DOI: 10.1038/leu.2008.350. View

17.

Sakurai H, Harada Y, Ogata Y, Kagiyama Y, Shingai N, Doki N . Overexpression of short isoform has an important role in the development of myelodysplastic/myeloproliferative neoplasms. Blood Adv. 2018; 1(18):1382-1386. PMC: 5727847. DOI: 10.1182/bloodadvances.2016002725. View

18.

Okuda T, van Deursen J, Hiebert S, Grosveld G, Downing J . AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996; 84(2):321-30. DOI: 10.1016/s0092-8674(00)80986-1. View

19.

Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe A, Speck N . Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A. 1996; 93(8):3444-9. PMC: 39628. DOI: 10.1073/pnas.93.8.3444. View

20.

Nottingham W, Jarratt A, Burgess M, Speck C, Cheng J, Prabhakar S . Runx1-mediated hematopoietic stem-cell emergence is controlled by a Gata/Ets/SCL-regulated enhancer. Blood. 2007; 110(13):4188-97. PMC: 2234795. DOI: 10.1182/blood-2007-07-100883. View